Last updated: 2026-10-09 17:48:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Context Therapeutics Inc. (CNTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.30, with a market capitalization of $28.72M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.30 to $3.62. This page covers its latest market performance, valuation, price trends and company information.
$28.72M | |
$0.30 | |
$10.87 | |
$0.30 | |
$0.30 | |
287.90K | |
1.62M | |
-- | |
$3.62 | |
$0.30 | |
-- | |
-- |
Context Therapeutics Inc. (CNTX) is currently trading at $0.30 as of 2026-10-09 17:46:00, up 1.67% ($0.01) from the previous close of $0.30
During today's regular trading session, CNTX has traded between $0.30 and $10.87, with a trading volume of 287.90K shares. The current price is near the lower end of today's range.
Over the past seven days, Context Therapeutics Inc. (CNTX) moved from $0.30 to $0.30, representing a gain of 1.20% ($0.00).
The stock traded between $0.30 and $0.36 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 849.87 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.3%
CNTX is currently trading at $0.30, placing it 0.3% of the way from its 52-week low of $0.30 to its 52-week high of $3.62. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 15 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Context Therapeutics Inc. (CNTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.